PTC Therapeutics, Inc. (PTCT)
Summary
PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript
PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
PTC Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 188 | $9,082.57 | $13,011.48 | $3,928.91 | 43.26% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 56 | $3,011.47 | $4,127.2 | $1,115.73 | 37.05% |
| BG Bart Gancher Intech Investment Management LLC | 57,581 | $3.37M | $4.22M | $850,488.07 | 25.23% |
| JM John Malone Amundi | 12,227 | $936,876.39 | $912,501.01 | -$24,375.38 | -2.6% |
 Anthony Scaramucci SkyBridge Capital II LLC | 1.07M | $32.73M | $76.82M | $44.09M | 134.72% |
PTC Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GM Geoff Meacham Citigroup | 1,345.2 | $99,141.54 | $96,451.13 | -$2,690.41 | -2.71% |
PTC Therapeutics, Inc. (PTCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has PTC Therapeutics, Inc. ever had a stock split?
PTC Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Matthew Klein CEO | NASDAQ (NGS) Exchange | 69366J200 CUSIP |
| US Country | 991 Employees | - Last Dividend | - Last Split | 20 Jun 2013 IPO Date |
Overview
PTC Therapeutics, Inc. is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of novel medicines for patients with rare disorders, both within the United States and internationally. Since its establishment in 1998, the company has been committed to addressing the needs of patients who suffer from rare diseases by leveraging innovative science and groundbreaking therapies. With its headquarters in South Plainfield, New Jersey, PTC Therapeutics has forged strategic collaborations with renowned entities such as F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. to expand its influence and reach in the rare disease space.
Products and Services
- Translarna and Emflaza
These products are specifically developed for the treatment of Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. Translarna and Emflaza aim to improve muscle strength and function in patients suffering from DMD.
- Upstaza
Upstaza is designed to treat aromatic L-amino acid decarboxylase (AADC) deficiency, a rare central nervous system disorder. This treatment targets the underlying cause of the disorder, aiming to improve motor function and quality of life for affected individuals.
- Tegsedi and Waylivra
These therapies are tailored for the treatment of rare diseases, with Tegsedi being approved for patients with hereditary TTR-mediated amyloidosis (hATTR) and Waylivra designated for familial chylomicronemia syndrome (FCS). They focus on reducing disease progression and alleviating symptoms.
- Evrysdi
Evrysdi is an oral treatment for spinal muscular atrophy (SMA) in adults and children, designed to increase the production of the survival motor neuron (SMN) protein, critical for muscle movement and strength.
- Sepiapterin for Phenylketonuria
This development stage product aims to treat phenylketonuria (PKU), a genetic disorder that increases the levels of phenylalanine in the blood, potentially leading to serious health problems.
- PTC518 Splicing Platform for Huntington's Disease
A cutting-edge development focused on Huntington's disease, this platform is designed to modulate splicing as a novel approach to treat this genetic disorder affecting the brain.
- Ferroptosis and Inflammation Platforms
These platforms include vatiquinone, intended for the treatment of Friedreich ataxia, and utreloxastat, aimed at combating amyotrophic lateral sclerosis (ALS). Both are part of PTC's efforts to target and treat neurodegenerative and rare diseases through innovative mechanisms.
